Clever Culture Systems Limited · ASX:CC5
Clever Culture Systems — NWR Virtual Small Cap Conference 2020
26 slides from Clever Culture Systems's conference presentation, Apr 30, 2020
Slide 1: Presentation at NWR Virtual Small Cap Conference
PRESENTATION AT NWR VIRTUAL SMALL CAP CONFERENCE May 1st, 2020. Virtual investor conference for health and medtech companies Adelaide, Australia, 30 April 2020: LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, announces
Slide 2: NWR Virtual Health Conference
NWR Virtual Health Conference Disruptive AI technology for healthcare Ready for launch May 2020 ASX code: LBT lbtinnovations.com
Slide 3: Disclaimer
Disclaimer This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct. Giv
Slide 4: Agenda
Agenda 1. Global Market Opportunity 2. APAS® Value Proposition 3. Future Outlook & Conclusions ASX code: LBT 3
Slide 5: Disruptive AI technology – commercial ready
Disruptive AI technology – commercial ready APAS® Independence - First and only automated culture plate reader Patent protected Global regulatory clearances Innovative platform technology Product launched - early sales ASX code: LBT 4
Slide 6: Challenges for microbiology laboratories
Challenges for microbiology laboratories Around the world scientists still read plates manually 2.4 billion plates per annum and growing ASX code: LBT 5
Slide 7: Challenges for microbiology laboratories
Challenges for microbiology laboratories Challenges Market Need Inconsistent results High demand Variability in plate reading 70% of clinical decisions based 12% Error rates up to 12% 70% on in vitro diagnostic results Workplace safety issues Inefficient use of resources Strain injuries caused by Up
Slide 8: Large addressable market
Large addressable market Compelling value proposition for medium and large laboratories Number of labs globally Small Labs <400 plates per day 15,000 Medium Labs 400 - 1000 plates per day 12,000 Delivering payback in 2 – 3 years Large Labs >1000 plates per day 1,000 Total Market Opportunity 13,000 A
Slide 9: Initial launch markets
Initial launch markets Current launch markets - 2,000 laboratories meeting APAS® target profile USA FDA Clearance CoE: Hennepin Health, MN ~1,500 Target Labs Australia >220 sales leads TGA established CoE: St Vincent’s, Melbourne >30 Target Labs 1st Sale St Vincent’s Hospital EU: UK and Germany CE M
Slide 10: APAS Independence
APAS® Independence The first and only automated culture plate reader - Powered by AI Clinically proven in a 10,000-patient clinical trial 3x faster + than manual culture plate reading Available regulatory cleared in US, EU, AU APAS® analysis modules Increases number of specimen + Attractive return o
Slide 11: Competitive landscape
Competitive landscape Competitors offer large and expensive process automation DO NOT read plates Automate lab workflow HIGH capital cost ~USD 2.5m+ cost Copan WASPLab™ LARGE footprint Complex installation LONG integration period Plates still read manually LOW penetration 150 units in 10 years BD Ki
Slide 12: First mover advantage - clinical plate reading
First mover advantage - clinical plate reading APAS® Independence uses AI for advanced decision making ONLY FDA CLEARED instrument Reads and interprets plates AFFORDABLE USD 300,000 SMALL footprint Plug and play START AND WALK AWAY Workflow efficiencies BROAD market opportunity Suitable for large an
Slide 13: Agenda
Agenda 1. Global Market Opportunity 2. APAS® Value Proposition 3. Future Outlook & Conclusions ASX code: LBT 12
Slide 14: Building the value proposition
Building the value proposition Multiple analysis modules provide increased value for all laboratories Manually read plates APAS ® read plates Cost and Time Savings Less manually Less FTEs read plates Increase ROI No APAS ® + APAS ® + APAS ® + APAS ® 1x AM 2x AM 3x AM Analysis Module = AM ASX code: L
Slide 15: Product roadmap - analysis module development
Product roadmap - analysis module development Increasing market opportunity More analysis modules > More laboratory tests > Increased ROI for labs Available 2020 Beyond Regulatory clearances - pending Future regulatory clearances required Urine MRSA* VRE Infection CRE Control + MRSA VRE Urine AST Wo
Slide 16: APAS ready for launch
APAS® ready for launch 2010 → 2018 2019 Targets 2020+ Early technology Regulatory clearances Market launch Distributor appointments development Market penetration - US, Establish KOLs Early sales Feasibility completion AU, DE, UK Market awareness Build sales pipeline New market expansion AM library
Slide 17: Sales model & market opportunity
Sales model & market opportunity Dual strategy of direct to market and distributor appointment 50:50 Joint Venture 1. CAPEX: Instrument 2. Annual Licenses: Profits shared equally ~USD 300k Analysis Module + Flexible leasing models ~USD 20k – 40k and SaaS established 5 year revenue opportunity ~USD 4
Slide 18: Comparable products case study
Comparable products case study Large market opportunity for laboratory automation Case Study Launch Sales Potential APAS Independence 2018 Launched with FDA Clearance 1,500 units after 10 years (and still growing) Cumulative instrument sales: ~USD 450 million 50% flows to LBT (after distributor fees
Slide 19: Agenda
Agenda 1. Global Market Opportunity 2. APAS® Value Proposition 3. Future Outlook & Conclusions ASX code: LBT 18
Slide 20: Business and commercialisation strategy
Business and commercialisation strategy Repeatable process: new opportunities - underpinned by core capability Developed internal capability Appoint distributors & build sales • Technology development • Routine clinical use in their market • In-sourced core capability • Demonstrate customer engageme
Slide 21: Strategic growth
Strategic growth Opportunity to extend platform capability into new applications Digital Pathology Machine Learning Process Laboratory Automation Wound Care Analytical Regulatory Studies Processes Digital Health Artificial Software Science Intelligence Engineering Medical Imaging Clinical Telehealth
Slide 22: Board and leadership team
Board and leadership team Damian Simon Lismore Arkell NED, AU NED, US Caroline Ray Popper Ridge NED, US CFO, AU Brent Barnes Kate Costello CEO and MD, AU Chairman, AU International board • 11 years senior executive at • Expertise in legal, corporate Cochlear Ltd (ASX: COH) governance and company str
Slide 23: Experienced management team
Experienced management team Peter Bradley Rhys Hill Julie Winson Steve Giglio VP Global Business Research Director Director Quality and Scientific Director Development APAS ® Inventor Regulatory Affairs 100yrs Artificial intelligence and Medical device Quality and regulatory Early product Microbiolo
Slide 24: Corporate overview
Corporate overview Key Statistics (Closing on 28 April 2020) Financials (AUD) Share Price $0.100 per share Current Cash $6.8 million (31 March 2020) 12-month range $0.067 - $0.24 $2.5m drawn down SAFA Loan Facility Number of shares 235.5 million Low interest rate, 5-year term Options Issued 6.1 mill
Slide 25: Investment highlights
Investment highlights Competitive positioning strong Large value proposition APAS® Independence - the only FDA and Initial launch market - 2,000 labs CE cleared product using artificial meet APAS® target profile intelligence for microbiology plate reading 5-year revenue opportunity ~USD Clinically p
Slide 26: LBT Innovations
LBT Innovations Level 8, 44 Waymouth Street Adelaide SA 5000 +61 (0)8 8227 1555 info@lbtinnovations.com lbtinnovations.com
Clever Culture Systems — NWR Virtual Small Cap Conference 2020 on 6ix